title: [Excess mortality from cardiovascular disease in patients with rheumatoid arthritis].
abstract: The cardiovascular morbidity and mortality are increased in rheumatoid arthritis and probably equal those of patients with type 2 diabetes mellitus. The European League Against Rheumatism has recently provided evidence-based guidelines for cardiovascular risk management in patients with rheumatoid arthritis and we here briefly summarise these guidelines and other recent data in this area of research.
authors.affiliation: Kardiologisk Afdeling P, Gentofte Hospital, Hellerup, Denmark. jesper@lindhardsen.net
authors.forename: Jesper
authors.initials: J
authors.lastname: Lindhardsen
authors.forename: Gunnar Hilmar
authors.initials: GH
authors.lastname: Gislason
authors.forename: Ole
authors.initials: O
authors.lastname: Ahlehoff
authors.forename: Ole Rintek
authors.initials: OR
authors.lastname: Madsen
authors.forename: Peter Riis
authors.initials: PR
authors.lastname: Hansen
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000209:etiology / Q000401:mortality*; D005060:Europe / Q000453:epidemiology; D006801:Humans; D017410:Practice Guidelines as Topic; D012307:Risk Factors
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D018501:Antirheumatic Agents